Laurus Labs Ltd

Laurus Labs | 540222

Market Closed

₹1,021.85

+₹0.00 (+2.29%)

As on 18/11/25, 9:32 PM

Market Cap53,928.51 CR

Current Price₹1,021.85

High / Low₹1,014.4 / 475.1

PE Ratio92.44

Book Value₹82.94

Dividend Yield0.20%

ROCE8.80%

ROE7.75%

Face Value₹2.00

Current Vol.16,96,744

Average Vol.12,76,53,456

ISININE947Q01028

PB Ratio7.4

Debt to Equity0.62

Net Profit Margin5.69

Operating Margin19.33

Stock cgart

Stock Performance

₹2,480₹2,490

₹2,500

Previous CloseToday's Open

₹1,800₹3,000

₹2,500

52W Low52W High

₹2,480Today's Open

₹2,490Previous Close

12,00,000Volume

₹1,80052W Low

₹3,00052W High

Ratios

No data available

About Company

Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company
The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007
Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007
Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007
Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology
The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others
With 12 manufacturing facilities - 8 operating facilities in Visakhapatnam, a drug substance unit and a kilo lab in Hyderabad, and two bio facilities in Bengaluru - which are accredited by global regulatory agencies, including the US FDA and WHO, Company ensure the highest quality standards in the production processes
The company's strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing 'donor-funded access-to-medicines markets' of Sub-Saharan Africa, South-East Asia and Latin America
The company also has growing synthesis and nutraceutical/ cosmeceutical ingredients businesses

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

;

Technical Indicators

RSI74.50

SMA 20965.26

SMA 50915.57

SMA 100869.21

SMA 200735.73

SMA 10991.44

MACD_12_26_Days29.41

EMA10Day989.82

EMA20Day966.48

EMA50Day921.61

MACD_12_26_9_Days2.68

EMA100Day861.66

EMA200Day768.73

Pivot Points

Volume Analysis

Growth Rate

Revenue Growth10.18%

ROE7.36%

EBITDA Margin19.33%

All figures in ₹ Crores

Indicators	2025	2024	2023	2022	2021
Revenue	5,553.96	5,040.83	6,040.55	4,935.57	4,813.51
Interest	216.00	182.90	165.17	102.39	68.16
Expenses	4,498.68	4,263.33	4,448.36	3,513.14	3,262.83
Financing Profit	1,130.38	803.84	1,598.19	1,437.73	1,574.34
Financing Margin %	20%	16%	26%	29%	33%
Other Income	75.10	26.34	6.00	15.30	23.66
Depreciation	430.09	384.58	324.08	251.49	205.07
Profit before tax	484.29	236.36	1,108.94	1,083.85	1,301.11
Tax %	27%	29%	28%	23%	24%
Net Profit	354.41	168.21	796.64	832.43	983.82
EPS in Rs	6.65	2.98	14.69	15.42	18.36

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

Deal	Date	Type	Quantity	Price	Traded %
ARUN VIJAY NATHANI	14 Mar ‘23	Purchase	6,35,894	₹305	42.52%
CYBAGE SOFTWARE PRIVATE LIMITED	14 Mar ‘23	Sell	6,35,894	₹305	42.52%
ISHARES CORE MSCI EMERGING MARKETS ETF	14 Nov ‘22	Purchase	5,29,337	₹455.4	43.30%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	14 Nov ‘22	Sell	5,29,337	₹455.4	43.30%
ISHARES CORE MSCI EMERGING MARKETS ETF	03 Nov ‘22	Purchase	5,29,338	₹476.6	66.29%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	03 Nov ‘22	Sell	5,29,338	₹476.6	66.29%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	03 Oct ‘22	Sell	4,37,878	₹513	47.23%
ISHARES CORE MSCI EMERGING MARKETS ETF	03 Oct ‘22	Purchase	4,37,878	₹513	47.23%
ISHARES INDIA SC MAURITIUS COMPANY	03 Oct ‘22	Sell	68,448	₹513	7.38%
ISHARES MSCI INDIA SMALL-CAP ETF	03 Oct ‘22	Purchase	68,448	₹513	7.38%

News

📊

No Information Available

No news available for this company.

Record Date

Corporate Action

Information

Announcement Day

31 Oct 2025

Interim Dividend (₹0.8)

The Board of Directors approved the payment of Interim Dividend of Rs.0.80/- (40%) per equity share of Rs.2/- each, for the Financial Year 2025-26. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed 'October 31, 2025' as the 'Record Date' for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 12, 2025.

23 Oct 2025

26 Jun 2025

AGM

15 May 2025

09 May 2025

Interim 2 Dividend (₹0.8)

Board Meeting Outcome for Board Meeting Outcome - 24.04.2025 The Board of Directors approved the payment of 2nd Interim Dividend of Rs.0.80/- (40%) per equity share of Rs.2/- each, for the Financial Year 2024-25. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed 'May 09, 2025' as the 'Record Date' for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 20, 2025.

24 Apr 2025

06 Nov 2024

Interim Dividend (₹0.4)

Approved the payment of Interim Dividend of Rs.0.40/- (20%) per equity share of Rs.2/- each, for the Financial Year 2024-25.

24 Oct 2024

11 Jul 2024

AGM

25 Apr 2024

08 May 2024

Interim 2 Dividend (₹0.4)

Approved the payment of 02nd interim dividend of Re. 0.40/- (20%) per equity share of Rs.2/- each, for the Financial Year 2023-24. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed 'May 08, 2024' as 'Record Date' for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 17, 2024.

25 Apr 2024

02 Nov 2023

Interim Dividend (₹0.4)

Interim Dividend FY 24 The Board of Directors of the Company in their meeting held on October 20, 2023 have approved for the payment of interim dividend of Rs. 0.40/- (20%) per equity share of Rs.2/- each, for the Financial Year 2023-24. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed 'October 30, 2023' as 'Record Date' for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 09, 2023. The Record Date for the payment of interim dividend which was informed earlier in the Corporate Action as 'October 30, 2023' to be read as 'November 02, 2023'. However, there is no change in the payment date as announced earlier, which is November 09, 2023.

20 Oct 2023

14 Jul 2023

AGM

27 Apr 2023

10 May 2023

Interim 2 Dividend (₹1.2)

The Board of Directors of the Company in their meeting held on April 27, 2023 have approved for the payment of 02nd interim dividend of Rs. 1.20/- (60%) per equity share of Rs.2/- each, for the Financial Year 2022-23. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed 'May 10, 2023' as 'Record Date' for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 18, 2023. The Board Meeting commenced at 02.00 PM and concluded at 02.45 PM.

27 Apr 2023

04 Nov 2022

Interim Dividend (₹0.8)

Board approved:- 1. Approved the payment of interim dividend of Rs. 0.80 (40%) per equity share of Rs.2/- each, for the Financial Year 2022-23.

21 Oct 2022

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
1,006	54,306	79	11	48	1	5.69%
1,760	4,22,211	37	5	30	0	20.88%
6,475	1,71,898	69	11	59	0	23.41%
3,793	1,28,372	59	15	43	1	16.60%
1,515	1,22,349	22	4	19	0	19.21%
1,244	1,03,789	18	3	14	0	17.54%
2,047	93,506	22	5	17	0	14.56%
928	93,404	19	4	15	0	19.86%
2,224	91,800	53	6	35	0	14.39%
1,240	72,630	21	2	14	0	10.98%

Showing 10 of 124 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in less than 10 mins*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

Frequently Asked Questions

What is Share Price of Laurus Labs Ltd?

The current share price of Laurus Labs Ltd (Laurus Labs) is ₹1021.85. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Laurus Labs Ltd?

The Price-to-Earnings (P/E) ratio of Laurus Labs Ltd is 1021.85. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Laurus Labs Ltd?

Laurus Labs Ltd has a 52-week high of ₹1014.40 and a 52-week low of ₹475.10. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Laurus Labs Ltd?

Laurus Labs Ltd offers a dividend yield of 0.12%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Laurus Labs Ltd?

The Earnings Per Share (EPS) of Laurus Labs Ltd is ₹12.67. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Laurus Labs Ltd?

Laurus Labs Ltd has a Return on Equity (ROE) of 7.75%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds.